52 related articles for article (PubMed ID: 1626110)
1. [The relationships between the lipoprotein profile and rheological-coagulation parameters in patients with hyperlipoproteinemia type II].
Bo M; Molaschi M; Neirotti M; Bonino F; Gottero M; Pedrazzini V; Mainardi S; Fabris F
Recenti Prog Med; 1992 Apr; 83(4):189-93. PubMed ID: 1626110
[TBL] [Abstract][Full Text] [Related]
2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
4. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
5. Factor VII and fibrinogen levels examined by age, sex, and other atherosclerotic risk factors in a Japanese population. The Jichi Medical School Cohort Study.
Ishikawa S; Kario K; Nago N; Kayaba K; Hiraoka J; Matsuo H; Goto T; Miyamoto T; Tsutsumi A; Nakamura Y; Shimada K; Inoue K; Igarashi M
Thromb Haemost; 1997 May; 77(5):890-3. PubMed ID: 9184398
[TBL] [Abstract][Full Text] [Related]
6. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
[TBL] [Abstract][Full Text] [Related]
7. Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II.
Atta M; Crook D; Shafique F; Johnston DG; Godsland IF
Thromb Haemost; 2008 Sep; 100(3):391-6. PubMed ID: 18766253
[TBL] [Abstract][Full Text] [Related]
8. Influence of plasmatic lipids on the hemorheological profile in healthy adults.
Contreras T; Vayá A; Palanca S; Solá E; Corella D; Aznar J
Clin Hemorheol Microcirc; 2004; 30(3-4):423-5. PubMed ID: 15258378
[TBL] [Abstract][Full Text] [Related]
9. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Freyberger H; Schifferdecker E; Schatz H
Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
[TBL] [Abstract][Full Text] [Related]
10. [Blood hyperviscosity syndromes].
Crepaldi G; Calabrò A; Belloni M; Ongaro G; Muggeo M
Ric Clin Lab; 1983; 13 Suppl 3():89-104. PubMed ID: 6424223
[TBL] [Abstract][Full Text] [Related]
11. [Hemostatic parameters in patients with type IIA and IV hyperlipoproteinemia].
Ferlito S; Torrisi A; Marangio S; Palermo A; Condorelli M; Mazzone D
Minerva Cardioangiol; 1992 Jun; 40(6):211-7. PubMed ID: 1407615
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population.
Barillari G; Fabbro E; Pasca S; Bigotto E
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):290-6. PubMed ID: 19318924
[TBL] [Abstract][Full Text] [Related]
13. Impact of pancreas and kidney transplantation on determinants of blood and plasma viscosity.
Mellinghoff AC; Reininger AJ; Wurzinger LJ; Landgraf R; Hepp KD
Clin Hemorheol Microcirc; 1998 Jul; 18(2-3):175-84. PubMed ID: 9699039
[TBL] [Abstract][Full Text] [Related]
14. [Apolipoprotein E and activity of cholesterol esters transport in type IIA and IIB hyperlipoproteinemia].
Tvorogova MG; Rozhkova TA; Semenova OA; Lupanov VP; Nuraliev EIu ; Kukharchuk VV; Titov VN
Ter Arkh; 1997; 69(12):30-3. PubMed ID: 9503530
[TBL] [Abstract][Full Text] [Related]
15. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
[TBL] [Abstract][Full Text] [Related]
16. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
17. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
18. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
20. Plasma thrombomodulin is not increased in familial hypercholesterolemic children with rheological alterations.
Vayá A; Martínez M; Dalmau J; Martí R; Ballesta A; Aznar J
Clin Hemorheol Microcirc; 1998 Oct; 19(2):133-8. PubMed ID: 9849926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
